

Pure Transplant Solutions Names Steven Lloyd Mayer, MD as Chief Medical Officer

OKLAHOMA CITY, OK and AUSTIN, TX – February 1, 2016 – Pure Transplant Solutions, L.L.C. (PTS), a developer of diagnostics and therapeutics for transplant medicine and autoimmunity, has announced the appointment of Dr. Steven Mayer as Chief Medical Officer. In this role, Dr. Mayer will lead PTS's clinical research strategies and support ongoing business development.

Dr. Mayer has more than 25 years of diversified experience in diagnostics, medical devices and drug development. From 2002 to 2015, he was a Scientific Consultant and an Advisor to several healthcare companies including: Abbott Labs, GlucoSentient, Inc., RulesBasedMedicine, IAPAC, MeadWestVaco, Xhale Diagnostics, Psynova Neurotech Ltd., Organ Recovery Systems and HBM BioVentures. From 1982 to 2002, Dr. Mayer held roles of increasing responsibility at Abbott Laboratories where he began as an engineer in Corporate Engineering; then as a Program Manager, Senior Strategic Planner, and Director of Health Economics in the Diagnostics Division; and lastly as a Medical Director of PharmacoEconomics and Outcomes Research and Associate Medical Director in Abbott's Pharmaceutical Products Division. Since 2003, Dr. Mayer has served as a member on numerous Boards including HBM BioVentures, Organ Recovery Systems, and is an active Member on Board of Directors for GlucoSentient, Inc. Dr. Mayer has Doctor of Medicine and B.S. Chemical Engineering degrees, both from the University of Wisconsin - Madison.

"I am very excited to join PTS and work with an exceptional team of talented professionals who have developed leading edge HLA technology which has the potential for significant benefits for patients, physicians and payers in the transplant industry" said Dr. Mayer.

"We are extremely fortunate to have Dr. Mayer join our leadership team," said Thomas Harlan, CEO of Pure Transplant Solutions. "Steven has the experience and expertise to help commercialize our Soluble HLA Antibody Removal Column (SHARC) platform and collaborate with the transplant community and industry partners to further demonstrate the clinical utility, improved patient outcomes and cost-effectiveness of SHARC."

About Pure Transplant Solutions

Pure Transplant Solutions, L.L.C. (PTS) is a subsidiary of Pure Protein L.L.C. (Pure Protein) that develops immunology tools for therapeutic and diagnostic applications in solid organ and stem cell transplantation, cross-reactive antibody screening, and major autoimmune diseases. PTS uses HLA protein to develop diagnostics, devices, and therapeutics that will reduce rejection in organ transplants. PTS and Pure Protein are

managed by innovation solutions company Emergent Technologies, Inc. For more information, please visit: www.puretransplant.com and www.pureproteinllc.com.

About Emergent Technologies

Austin, TX based Emergent Technologies, Inc. (Emergent) is a leading innovation solutions company that identifies, manages, develops and partners to turn game-changing scientific discoveries into market-driven products. Emergent's diverse business and technical team uses its unique innovation process to transform scientific breakthroughs into technology platforms with multiple applications, maximizing the value of promising ideas and underutilized intellectual properties without the risk associated with commercial development. The company applies its experience and expertise to provide investors, entrepreneurs, start-up companies and industry partners' access to innovative solutions to advance initiatives and protect and grow core businesses with novel, differentiating technology. For more information, visit www.emergenttechnologies.com.

###

Media Contact:
Cameron Mackie
Email: cmackie@emergenttechnologies.com
Phone: 512.263.3232